{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that median and upper limit of confidence interval (CI) were not estimable due to insufficient number of participants with events at study closure.","groupId":"OG000","lowerLimit":"6.8","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"DoR by ICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.9","upperLimit":"18.1","value":"11.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"DoR by Investigator assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression (date of progression-free survival \\[PFS\\] event or censoring - date of first response + 1). The DoR was calculated using Kaplan-Meier technique.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.","id":"OG000","title":"T-DXd"}],"paramType":"MEDIAN","populationDescription":"The FAS consisted of all participants who received at least 1 dose of study treatment. Participants with response were evaluated.","reportingStatus":"POSTED","timeFrame":"Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)","title":"Duration of Response (DoR) as Per RECIST v1.1 Using ICR and Investigator Assessment","type":"SECONDARY","unitOfMeasure":"months"}